Brief: Immutep’S Efti With Radiotherapy & KEYTRUDA® Meets Primary Endpoint In Phase 2 For Soft Tissue Sarcoma
27/05/2025 13:44
May 27 (Reuters) - Immutep Ltd IMM.AX: IMMUTEP’S EFTI WITH RADIOTHERAPY & KEYTRUDA® (PEMBROLIZUMAB) MEETS PRIMARY ENDPOINT IN PHASE II FOR SOFT TISSUE SARCOMA Source text: ID:nGNXNlVJL Further company coverage: IMM.AX ((Reuters.Briefs@thomsonreuters.com;))